Global Lung Cancer Therapeutics Market to Reach $11 Billion by 2020 - Growing Demand for Targeted Therapies - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Lung Cancer Therapeutics Market 2016-2020" report to their offering.

The report forecasts the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, the market has been witnessing an increased demand for immune-based therapies such as checkpoint inhibitors. There are various types of checkpoint inhibitors that target different checkpoints on immune cells. These treatments work by allowing to mount a stronger and effective attack against lung cancer. The traditional chemotherapy approach involves the destruction of cancerous cells as well as nearby benign cells. This will create a lot of side effects and affects the patient compliance.

Key vendors:

  • F. Hofmann-La Roche
  • Eli Lilly
  • AstraZeneca
  • Pfizer
  • Celgene

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by disease type

Part 09: Market segmentation by type of molecule

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Key vendor analysis

Part 18: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/xsfb2p/global_lung

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Lung Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Lung Cancer Drugs